Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

NCT04924413 is registered in ClinicalTrials.gov with Quanli Gao as lead sponsor.

NCT NCT04924413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04924413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
Lead sponsor
Quanli Gao
Phase
Phase 2
Overall status
Terminated
Start date
July 1, 2021
Completion date
July 2, 2024
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma